Xellia Pharmaceuticals, SINTEF Materials and Chemistry, and the Statens Serum Institut, have entered a collaboration agreement to develop new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria. The four-year project is being supported by a $3 million grant from the Research Council of Norway (NFR), and also includes contributions from labs across Europe.   Xellia aims to develop new antibiotics that target Gram-negative bacterial infections, caused by Pseudomonas, K...